Linked Life Data

16316459

Source:http://linkedlifedata.com/resource/pubmed/id/16316459

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:dateCreated
2005-12-16
pubmed:abstractText
This phase II study evaluated the efficacy and safety of gemcitabine (G) plus paclitaxel (T) as first-line therapy in recurrent or metastatic breast cancer.
pubmed:commentsCorrections
http://linkedlifedata.com/resource/pubmed/commentcorrection/16316459-10211545, http://linkedlifedata.com/resource/pubmed/commentcorrection/16316459-10507311, http://linkedlifedata.com/resource/pubmed/commentcorrection/16316459-10561275, http://linkedlifedata.com/resource/pubmed/commentcorrection/16316459-10697032, http://linkedlifedata.com/resource/pubmed/commentcorrection/16316459-10993656, http://linkedlifedata.com/resource/pubmed/commentcorrection/16316459-10997809, http://linkedlifedata.com/resource/pubmed/commentcorrection/16316459-11368414, http://linkedlifedata.com/resource/pubmed/commentcorrection/16316459-11404498, http://linkedlifedata.com/resource/pubmed/commentcorrection/16316459-11408796, http://linkedlifedata.com/resource/pubmed/commentcorrection/16316459-11709565, http://linkedlifedata.com/resource/pubmed/commentcorrection/16316459-11810037, http://linkedlifedata.com/resource/pubmed/commentcorrection/16316459-11814064, http://linkedlifedata.com/resource/pubmed/commentcorrection/16316459-12065558, http://linkedlifedata.com/resource/pubmed/commentcorrection/16316459-1283847, http://linkedlifedata.com/resource/pubmed/commentcorrection/16316459-14965758, http://linkedlifedata.com/resource/pubmed/commentcorrection/16316459-15031594, http://linkedlifedata.com/resource/pubmed/commentcorrection/16316459-15169793, http://linkedlifedata.com/resource/pubmed/commentcorrection/16316459-1683908, http://linkedlifedata.com/resource/pubmed/commentcorrection/16316459-1973737, http://linkedlifedata.com/resource/pubmed/commentcorrection/16316459-7537798, http://linkedlifedata.com/resource/pubmed/commentcorrection/16316459-7543562, http://linkedlifedata.com/resource/pubmed/commentcorrection/16316459-7595731, http://linkedlifedata.com/resource/pubmed/commentcorrection/16316459-7912522, http://linkedlifedata.com/resource/pubmed/commentcorrection/16316459-7915153, http://linkedlifedata.com/resource/pubmed/commentcorrection/16316459-8656254, http://linkedlifedata.com/resource/pubmed/commentcorrection/16316459-9062409, http://linkedlifedata.com/resource/pubmed/commentcorrection/16316459-9735415, http://linkedlifedata.com/resource/pubmed/commentcorrection/16316459-9779724
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:issn
1471-2407
pubmed:author
pubmed:issnType
Electronic
pubmed:volume
5
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
151
pubmed:dateRevised
2009-11-18
pubmed:meshHeading
pubmed-meshheading:16316459-Adult, pubmed-meshheading:16316459-Aged, pubmed-meshheading:16316459-Antineoplastic Combined Chemotherapy Protocols, pubmed-meshheading:16316459-Breast Neoplasms, pubmed-meshheading:16316459-Deoxycytidine, pubmed-meshheading:16316459-Disease Progression, pubmed-meshheading:16316459-Disease-Free Survival, pubmed-meshheading:16316459-Dose-Response Relationship, Drug, pubmed-meshheading:16316459-Female, pubmed-meshheading:16316459-Humans, pubmed-meshheading:16316459-Middle Aged, pubmed-meshheading:16316459-Neoplasm Metastasis, pubmed-meshheading:16316459-Paclitaxel, pubmed-meshheading:16316459-Prognosis, pubmed-meshheading:16316459-Recurrence, pubmed-meshheading:16316459-Remission Induction, pubmed-meshheading:16316459-Time Factors, pubmed-meshheading:16316459-Treatment Outcome
pubmed:year
2005
pubmed:articleTitle
First-line therapy with gemcitabine and paclitaxel in locally, recurrent or metastatic breast cancer: a phase II study.
pubmed:affiliation
Centre F. Baclesse, Lion Sur Mer, 14076 Caen Cedex 05, France. d.allouache@baclesse.fr
pubmed:publicationType
Journal Article, Research Support, Non-U.S. Gov't, Clinical Trial, Phase II